Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism HIF-2α inhibitors(Endothelial PAS domain-containing protein 1 inhibitors), JNK inhibitors(c-Jun N-terminal kinase inhibitors), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC15H12O8 |
InChIKeyMYUBTSPIIFYCIU-UHFFFAOYSA-N |
CAS Registry654055-01-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | India | 01 Oct 2025 | |
Chemical and Drug Induced Liver Injury, Chronic | Preclinical | India | 26 Jun 2025 | |
Nephrotoxicity | Preclinical | India | 08 May 2025 | |
Huntington Disease | Preclinical | Egypt | 01 Feb 2024 |